# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: TDM2/26 - Léky

Stop termín: 9.10.2026

Nastavení: skupiny - M (princip měření); Slovensko; minimální četnost skupin n = 5

RoM = robustní průměr
SD = směrodatná odchylka
CV = variační koeficient
$N_{tot}$ = celkový počet výsledků
$N_{out}$ = počet výsledků vyloučených před výpočtem
AV = vztažná hodnota
CVP = konsenzus všech účastníků
$U_{AV}$ = rozšířená nejistota vztažné hodnoty (k = 2)
$D_{max}$ = přijatelný rozdíl
LL = dolní mez
UL = horní mez
$N_{eva}$ = počet hodnocených výsledků
$N_{suc}$ = počet úspěšných výsledků
$S_{rel}$ = relativní úspěšnost

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Sada 1** | | | | | | | | | | | | | | | |
| (81) **Digoxin** | [µg/L] | | | | 15 | | | | | | | | 15 | 14 | 93 |
| **Vzorek A1** | | 0,941 | 0,073 | 7,8 | 15 | | CVP | 0,963 | 0,028 | 30% | 0,674 | 1,26 | 15 | 14 | 93 |
| (4) LIA, ILMA | | 0,963 | 0,085 | 8,8 | 5 | 0 | | | | | | | 5 | | |
| (6) Imunoturbidimetrie, KIMS | | 0,909 | 0,042 | 4,7 | 5 | 0 | | | | | | | 5 | | |
| Ostatní | | | | | 5 | 0 | | | | | | | 5 | | |
| | | | | | | | 4x 2, 1x 99 | | | | | | | | |
| **Vzorek B1** | | 1,11 | 0,077 | 7 | 15 | | CVP | 1,13 | 0,027 | 30% | 0,791 | 1,47 | 15 | 15 | 100 |
| (4) LIA, ILMA | | 1,07 | 0,059 | 5,5 | 5 | 0 | | | | | | | 5 | | |
| (6) Imunoturbidimetrie, KIMS | | 1,1 | 0,046 | 4,2 | 5 | 0 | | | | | | | 5 | | |
| Ostatní | | | | | 5 | 0 | | | | | | | 5 | | |
| | | | | | | | 4x 2, 1x 99 | | | | | | | | |
| (84) **Fenobarbital** | [mg/L] | | | | 5 | | | | | | | | 5 | 5 | 100 |
| **Vzorek A1** | | 27,9 | 0,86 | 3,1 | 5 | | CVP | 28,5 | 1,3 | 20% | 22,8 | 34,2 | 5 | 5 | 100 |
| Ostatní | | | | | 5 | 0 | | | | | | | 5 | | |
| | | | | | | | 2x 2, 1x 3, 2x 6 | | | | | | | | |
| **Vzorek B1** | | 18,7 | 0,56 | 3 | 5 | | CVP | 19,1 | 0,68 | 20% | 15,2 | 23 | 5 | 5 | 100 |
| Ostatní | | | | | 5 | 0 | | | | | | | 5 | | |
| | | | | | | | 2x 2, 1x 3, 2x 6 | | | | | | | | |
| (85) **Fenytoin** | [mg/L] | | | | 1 | | | | | | | | 1 | 1 | 100 |
| **Vzorek A1** | | 7,11 | | | 1 | | CVP | 6,95 | 0,27 | 20% | 5,56 | 8,34 | 1 | 1 | 100 |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | |
| | | | | | | | 1x 2 | | | | | | | | |
| **Vzorek B1** | | 22,8 | | | 1 | | CVP | 23 | 0,79 | 20% | 18,4 | 27,6 | 1 | 1 | 100 |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | |
| | | | | | | | 1x 2 | | | | | | | | |
| (86) **Karbamazepin** | [mg/L] | | | | 7 | | | | | | | | 7 | 7 | 100 |
| **Vzorek A1** | | 12,8 | 0,9 | 7,1 | 7 | | CVP | 13 | 0,33 | 20% | 10,4 | 15,6 | 7 | 7 | 100 |
| Ostatní | | | | | 7 | 0 | | | | | | | 7 | | |
| | | | | | | | 3x 2, 1x 4, 3x 6 | | | | | | | | |
| **Vzorek B1** | | 10,3 | 1,1 | 11 | 7 | | CVP | 10,4 | 0,22 | 20% | 8,32 | 12,5 | 7 | 7 | 100 |
| Ostatní | | | | | 7 | 0 | | | | | | | 7 | | |
| | | | | | | | 3x 2, 1x 4, 3x 6 | | | | | | | | |
| (88) **Kyselina valproová** | [mg/L] | | | | 12 | | | | | | | | 12 | 11 | 92 |
| **Vzorek A1** | | 60,2 | 5 | 8,3 | 12 | | CVP | 59,4 | 1 | 20% | 47,5 | 71,3 | 12 | 11 | 92 |
| (2) EIA (EMIT, CEDIA) | | 62,8 | 6,2 | 9,9 | 6 | 0 | | | | | | | 6 | | |
| (6) Imunoturbidimetrie, KIMS | | 56,4 | 0,83 | 1,5 | 5 | 0 | | | | | | | 5 | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | |
| | | | | | | | 1x 4 | | | | | | | | |
| **Vzorek B1** | | 99,5 | 5,8 | 5,8 | 12 | | CVP | 97,9 | 1,4 | 20% | 78,3 | 118 | 12 | 12 | 100 |
| (2) EIA (EMIT, CEDIA) | | 101 | 4,2 | 4,1 | 6 | 0 | | | | | | | 6 | | |
| (6) Imunoturbidimetrie, KIMS | | 98 | 6 | 6,1 | 5 | 0 | | | | | | | 5 | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | |
| | | | | | | | 1x 4 | | | | | | | | |
| (91) **Lithium** | [mmol/L] | | | | 5 | | | | | | | | 5 | 4 | 80 |
| **Vzorek A1** | | | | | | | | | | | | | 5 | 5 | 100 |
| (5) Spektrofotometrie | | 1,05 | 0,045 | 4,2 | 5 | 0 | CVP | 1,09 | 0,02 | 12% | 0,959 | 1,23 | 5 | | |
| **Vzorek B1** | | | | | | | | | | | | | 5 | 4 | 80 |
| (5) Spektrofotometrie | | 0,48 | 0,03 | 6,2 | 5 | 0 | CVP | 0,518 | 0,016 | 12% | 0,455 | 0,581 | 5 | | |
| (82) **Teofylin** | [mg/L] | | | | 3 | | | | | | | | 3 | 3 | 100 |
| **Vzorek A1** | | 15,3 | 1,4 | 9,1 | 3 | | CVP | 15 | 0,23 | 19% | 12,1 | 17,9 | 3 | 3 | 100 |
| Ostatní | | | | | 3 | 0 | | | | | | | 3 | | |
| | | | | | | | 3x 2 | | | | | | | | |
| **Vzorek B1** | | 17 | 1 | 5,9 | 3 | | CVP | 16,5 | 0,24 | 19% | 13,3 | 19,7 | 3 | 3 | 100 |
| Ostatní | | | | | 3 | 0 | | | | | | | 3 | | |
| | | | | | | | 3x 2 | | | | | | | | |
| **Sada 2** | | | | | | | | | | | | | | | |
| (89) **Amikacin** | [mg/L] | | | | 8 | | | | | | | | 8 | 7 | 88 |
| **Vzorek A2** | | 6,5 | 0,74 | 11 | 8 | | CVP | 7,01 | 0,21 | 20% | 5,6 | 8,42 | 8 | 7 | 88 |
| (2) EIA (EMIT, CEDIA) | | 6,95 | 0,074 | 1,1 | 5 | 0 | | | | | | | 5 | | |
| Ostatní | | | | | 3 | 0 | | | | | | | 3 | | |
| | | | | | | | 3x 6 | | | | | | | | |
| **Vzorek B2** | | 13,9 | 0,79 | 5,6 | 8 | | CVP | 14,2 | 0,25 | 20% | 11,3 | 17,1 | 8 | 8 | 100 |
| (2) EIA (EMIT, CEDIA) | | 13,8 | 0,59 | 4,3 | 5 | 0 | | | | | | | 5 | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: TDM2/26 - Léky

Stop termín: 9.10.2026

Nastavení: skupiny - M (princip měření); Slovensko; minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ostatní | | | | | 3 | 0 | | | | | | | 3 | | |
| | | | | | | | 3x 6 | | | | | | | | |
| (90) **Gentamicin** | [mg/L] | | | | 14 | | | | | | | | 14 | 13 | 93 |
| **Vzorek A2** | | 4,17 | 0,68 | 16 | 14 | | | | | | | | 14 | 13 | 93 |
| (2) EIA (EMIT, CEDIA) | | 4,77 | 0,84 | 18 | 6 | 0 | CVP | 4,21 | 0,13 | 31% | 2,9 | 5,52 | 6 | | |
| Ostatní | | | | | 8 | 0 | | | | | | | 8 | | |
| | | | | | | | 2x 4, 3x 6, 3x 6/60 | | | | | | | | |
| **Vzorek B2** | | 7,68 | 1,3 | 16 | 14 | | | | | | | | 14 | 14 | 100 |
| (2) EIA (EMIT, CEDIA) | | 8,6 | 0,74 | 8,6 | 6 | 0 | CVP | 7,6 | 0,24 | 31% | 5,24 | 9,96 | 6 | | |
| Ostatní | | | | | 8 | 0 | | | | | | | 8 | | |
| | | | | | | | 2x 4, 3x 6, 3x 6/60 | | | | | | | | |
| (93) **Metotrexát** | [µmol/L] | | | | 4 | | | | | | | | 4 | 3 | 75 |
| **Vzorek A2** | | 0,093 | 0,025 | 27 | 4 | | CVP | 0,083 | 0,006 | 30% | 0,058 | 0,108 | 4 | 3 | 75 |
| Ostatní | | | | | 4 | 0 | | | | | | | 4 | | |
| | | | | | | | 1x 2, 3x 4 | | | | | | | | |
| **Vzorek B2** | | 3,66 | 0,65 | 18 | 4 | | CVP | 3,54 | 0,2 | 30% | 2,47 | 4,61 | 4 | 4 | 100 |
| Ostatní | | | | | 4 | 0 | | | | | | | 4 | | |
| | | | | | | | 1x 2, 3x 4 | | | | | | | | |
| (94) **Paracetamol** | [mg/L] | | | | 4 | | | | | | | | 4 | 3 | 75 |
| **Vzorek A2** | | 20,5 | 3,7 | 18 | 4 | | CVP | 18,6 | 0,69 | 20% | 14,8 | 22,4 | 4 | 3 | 75 |
| Ostatní | | | | | 4 | 0 | | | | | | | 4 | | |
| | | | | | | | 3x 2, 1x 99 | | | | | | | | |
| **Vzorek B2** | | 37,8 | 5,3 | 14 | 4 | | CVP | 34,4 | 1,1 | 20% | 27,5 | 41,3 | 4 | 3 | 75 |
| Ostatní | | | | | 4 | 0 | | | | | | | 4 | | |
| | | | | | | | 3x 2, 1x 99 | | | | | | | | |
| (92) **Vankomycin** | [mg/L] | | | | 16 | | | | | | | | 16 | 16 | 100 |
| **Vzorek A2** | | 12,8 | 1,3 | 10 | 16 | | CVP | 12,8 | 0,28 | 28% | 9,21 | 16,4 | 16 | 16 | 100 |
| (2) EIA (EMIT, CEDIA) | | 11,9 | 1,1 | 9,4 | 7 | 0 | | | | | | | 7 | | |
| (6) Imunoturbidimetrie, KIMS | | 13,4 | 0,76 | 5,7 | 8 | 0 | | | | | | | 8 | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | |
| | | | | | | | 1x 4 | | | | | | | | |
| **Vzorek B2** | | 29,4 | 3,5 | 12 | 16 | | CVP | 29,7 | 0,69 | 28% | 21,3 | 38,1 | 16 | 16 | 100 |
| (2) EIA (EMIT, CEDIA) | | 27 | 2,4 | 9,1 | 7 | 0 | | | | | | | 7 | | |
| (6) Imunoturbidimetrie, KIMS | | 31,1 | 2,6 | 8,4 | 8 | 0 | | | | | | | 8 | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | |
| | | | | | | | 1x 4 | | | | | | | | |